All G
All G is an Australian biotechnology company that uses precision fermentation to produce bio-identical milk proteins, including LFX™ bovine lactoferrin, human lactoferrin, micellar caseins, and human milk proteins. It supplies these ingredients to global infant formula, dietary supplement, personal care, and functional food manufacturers.
- Company typePrivate
- Founded2021
- HeadquartersSydney, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What All G does
All G is an Australian biotechnology company founded in 2021 and headquartered in Sydney that develops and produces bio-identical milk proteins using precision fermentation technology. The company's core technical platform programs food-grade yeast microorganisms with DNA instructions to ferment high-value milk proteins, which are then purified through downstream processing and characterized using HPLC, LC-MS, and other analytical methods. Its product portfolio centres on LFX™ Bovine Lactoferrin — a >95% purity precision-fermented lactoferrin claimed to have higher iron-binding capacity and antioxidant activity than native bovine lactoferrin — alongside Human Lactoferrin, Micellar Caseins, and a broader Human Milk Proteins pipeline targeting breast-milk-equivalent infant formulations.
The company operates a B2B ingredient supply model, selling lactoferrin and human milk proteins to global enterprise customers in infant formula, dietary supplements, personal care, and functional foods and beverages. Pricing is quote-based and not publicly disclosed. All G supports customers with technical expertise, regulatory documentation, clinical trial data, and claims dossiers to enable product development and market entry across North America, Europe, Asia-Pacific, and China. Manufacturing at commercial scale is executed through a joint venture with Armor Protéines (Savencia Group) established December 2025, with additional pilot scale infrastructure via Doehler Ventures in Germany. Sales-led and channel-partner GTM motions are used in parallel.
The company has secured meaningful regulatory milestones that anchor its commercial positioning: world's first China CSAR approval for recombinant bovine lactoferrin (November 2024), US FDA self-affirmed GRAS status (late 2024), and an FDA 'no questions' letter (April 2026). These approvals in the two largest lactoferrin markets create a first-mover regulatory advantage. All G has raised over $56M USD across multiple funding rounds, with cumulative support from Agronomics Limited, CEFC, W23 (Woolworths), New Agrarian Company, Ellerston Capital, Doehler Ventures, and Triplestar. Commercial-scale production commenced in 2026, marking the transition from R&D to revenue-generating operations.
All G firmographics
Firmographics- Name
- All G
- Legal name
- All G Co Holdings Pty Limited
- Website
- https://allg.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- All G is an Australian biotechnology company that uses precision fermentation to produce bio-identical milk proteins, including LFX™ bovine lactoferrin, human lactoferrin, micellar caseins, and human milk proteins. It supplies these ingredients to global infant formula, dietary supplement, personal care, and functional food manufacturers.
- Ownership category
- akta.pro rank
All G industry classification
Industry- Product category
- Precision Fermentation Protein Ingredients
- NAICS
- Dairy Product Manufacturing (3115)
- SIC
- Dairy Products (2020)
- akta.pro primary industry
- Precision-Fermentation Dairy Analogues Processing (Animal-Free Whey/Casein Products) (AFAHAJAJ)
- akta.pro secondary industries
- Whey, Casein & Milk Protein Ingredient Manufacturing (AFAKAKAF), Infant Formula & Specialized Dairy Nutrition Manufacturing (AFAKAKAJ), Dairy Protein Ingredients (Whey, Casein/Caseinates, Milk Protein Concentrates/Isolates) (AFAJAHAC)
Keywords
Where All G is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
All G business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Ingredient Sales — Lactoferrin and Milk Proteins: All G generates revenue through the sale of precision-fermented lactoferrin ingredients (LFX™) to manufacturers of functional foods, beverages, dietary supplements, personal care products, and infant formula. The company has received regulatory approvals in the US (FDA 'no questions' letter / GRAS) and China (CSAR), enabling commercial ingredient sales. Revenue-generating phase began in 2026 following commercial-scale production commencement.
- Technical and Regulatory Services: All G supports partners and customers with regulatory documentation, clinical trial data, claims dossiers, ingredient data, and technical expertise across global markets including dietary supplement, infant formula, and personal care. This supports customer product development and market entry.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
All G product offering
Product offeringCore offering
All G develops and supplies high-purity bioactive milk proteins—including LFX™ bovine lactoferrin, human lactoferrin, micellar caseins, and human milk proteins—manufactured via precision fermentation of food-grade yeast. These protein ingredients are sold B2B to global manufacturers of infant formula, dietary supplements, functional foods/beverages, and personal care products, with bundled technical, regulatory, and clinical support. Commercial-scale production commenced in 2026 through a joint venture with Armor Protéines (Savencia Group).
Product overview
All G is an Australian biotechnology company that develops high-value human and bovine milk proteins through precision fermentation. The core product portfolio includes LFX™ Bovine Lactoferrin as the lead commercial product, along with Human Lactoferrin, Micellar Caseins, and Human Milk Proteins. The company also produced Love BUDS Burgers as its first consumer product. All products are produced using precision fermentation technology where microbes are programmed with DNA instructions and grown in fermentation tanks to produce bio-identical proteins. The product pipeline targets applications across infant formula, dietary supplements, personal care, and functional foods.
Differentiator
Problem solved
Functional benefit
Brands
- LFX™: Precision-fermented bovine lactoferrin ingredient with >95% purity, bio-equivalent to animal-based lactoferrin.
Products and services
- LFX™ Bovine Lactoferrin Precision-fermented bovine lactoferrin ingredient produced via microbial fermentation of food-grade yeast, offering >95% purity, bio-equivalent activity to animal-based lactoferrin, higher iron-binding capacity, and higher antioxidant activity. Designed for use in functional foods, beverages, dietary supplements, and personal care formulations by global manufacturers.
- Human Lactoferrin Precision-fermented human lactoferrin protein produced via microbial fermentation. Adapted specifically to human biology, binding and delivering iron with high bioavailability. Naturally occurring in saliva, tears, and protective mucosal fluids. Designed for infant formula, dietary supplements, and advanced nutrition applications.
- Micellar Caseins Precision-fermented micellar casein proteins that self-assemble into microscopic spheres with calcium and phosphate, mimicking the natural micellar structure found in milk. All G has filed patents covering stable casein micelle production from single casein protein types. Designed for infant formula and nutritional applications.
- Human Milk Proteins Precision-fermented human milk proteins including human casein micelles and other breast milk proteins for infant formula and nutritional applications, developed to more closely align with the composition and function of human breast milk. Includes patented infant formulations containing five major human breast milk proteins.
- Love BUDS Burgers Plant-based burger product developed using precision fermentation technology, launched as All G's first commercial product in Australian supermarkets.
Quantifiable outcome
- Lactoferrin supplementation was associated with reduced systemic inflammation, improvements in immune function, and a lower incidence of respiratory tract infections in infants and children (meta-analysis of clinical trials)
- +4 more outcomes
Companies that use All G
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
All G technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
All G partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Armor Protéines (Savencia Group)coreAll G formed a strategic joint venture with French lactoferrin producer Armor Protéines (owned by dairy major Savencia) to produce and commercialize bovine lactoferrin and human milk proteins at global scale. The JV combines All G's precision fermentation technology with Armor Protéines' established manufacturing infrastructure, supporting All G's first product launch of recombinant lactoferrin in 2026.
- Doehler VenturescoreAll G partnered with Doehler Ventures to establish a dedicated pilot facility in Germany supporting scale-up of precision fermentation production. Doehler Ventures also participated as an investor in All G's $10M convertible note fundraise in December 2025.
- University of SydneycoreAll G partnered with the University of Sydney for research collaboration as part of its founding strategy in 2021. The partnership supports the development of alternative proteins through academic research and expertise.
- University of Queensland (FaBA)coreAll G is scaling up lactoferrin production through partnerships with the University of Queensland's FaBA (Food and Beverage Accelerator), which supports advanced food and biotechnology manufacturing capabilities.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
All G competitors and assessment
Company assessmentDirect peers
- Helaina: US-based precision fermentation company developing recombinant human lactoferrin and other bioactive proteins for infant formula and supplements — the closest direct competitor to All G's LFX™ product line.
- Perfect Day: US precision fermentation leader producing animal-free whey protein for dairy applications; a broad platform competitor using similar microbial fermentation technology targeting B2B food and nutrition customers.
- Remilk: Israel-based precision fermentation company producing animal-free whey and casein proteins for dairy and infant nutrition — directly comparable technology platform and end-markets to All G.
- TurtleTree: Singapore/US precision fermentation company producing recombinant lactoferrin and other milk proteins using similar microbial host technology — direct overlap with All G's lactoferrin focus.
- Imagindairy: Israel-based precision fermentation startup producing animal-free casein and whey proteins for dairy alternatives, applying analogous fermentation approaches for B2B dairy ingredient customers.
- Those Vegan Cowboys: Belgium-based precision fermentation company producing animal-free casein proteins for cheese applications — comparable microbial fermentation platform targeting dairy protein markets.
- Formo: Germany-based precision fermentation company producing animal-free cheese proteins using microbial fermentation — comparable technology and European market overlap with All G's German pilot facility via Doehler.
Emerging players
- Vivici: Netherlands-based precision fermentation startup backed by DSM-Firmenich developing animal-free dairy proteins including lactoferrin — emerging competitor with corporate backing targeting overlapping B2B ingredient customers.
- Bon Vivant: France-based precision fermentation company producing animal-free whey proteins for dairy applications — emerging competitor with overlap in European precision-fermented dairy protein markets.
Others
- Armor Protéines (Savencia): French lactoferrin producer and All G's JV partner under Savencia Group — comparable as the leading animal-derived lactoferrin incumbent, with JV relationship creating both partnership and competitive dynamics for All G.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
All G social profiles
Digital presenceAll G compliance and trust
Trust signalCompliance4 records
All G financial estimates
Financial estimateRevenue estimate
Valuation estimate
All G leadership team
Management profileNumber of profiles
Profiles6 records
All G subsidiaries and ownership
Company hierarchySubsidiaries1 record
All G funding detail
Funding detailFunding overview
Funding rounds5 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
All G M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about All G
What does All G do?
All G develops and supplies high-purity bioactive milk proteins—including LFX™ bovine lactoferrin, human lactoferrin, micellar caseins, and human milk proteins—manufactured via precision fermentation of food-grade yeast. These protein ingredients are sold B2B to global manufacturers of infant formula, dietary supplements, functional foods/beverages, and personal care products, with bundled technical, regulatory, and clinical support. Commercial-scale production commenced in 2026 through a joint venture with Armor Protéines (Savencia Group).
Is All G a public or private company?
All G is a private company. It is classified as venture growth investor backed and is currently operating.
When was All G founded?
All G was founded in 2021. It employs 11 to 50 people.
Where is All G based?
All G is headquartered in Sydney, Australia, in the Oceania region.
How does All G make money?
Two revenue lines are on record. Ingredient Sales — Lactoferrin and Milk Proteins are the primary driver. The others are technical and Regulatory Services.
Who are All G's main competitors?
Direct peers on record are Helaina, Perfect Day, Remilk, TurtleTree, Imagindairy, Those Vegan Cowboys and Formo. Emerging players are Vivici and Bon Vivant. Armor Protéines (Savencia) is listed as an others.
Does All G have an API?
No public API is recorded for All G.
What industry is All G in?
All G's product category is Precision Fermentation Protein Ingredients. Its primary akta.pro industry code is AFAHAJAJ, Precision-Fermentation Dairy Analogues Processing (Animal-Free Whey/Casein Products), with a secondary code of AFAKAKAF, Whey, Casein & Milk Protein Ingredient Manufacturing. Its NAICS code is 3115 and its SIC code is 2020.